Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 11/20 | 0.46 |
| ▸ | GSK3B | P49841 | 11/20 | 0.46 |
| ▸ | PIM1 | P11309 | 10/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 9/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | PAK4 | O96013 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.44 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.44 |
| ▸ | CDC7 | O00311 | 5/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.43 |
| ▸ | CLK1 | P49759 | 2/20 | 0.43 |
| ▸ | CLK2 | P49760 | 2/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.43 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.43 |
| ▸ | CLK3 | P49761 | 1/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.43 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL560911 | 0.77 | PIK3CA (0.59) | ROCK2ROCK1NOS1MAPK1 | |
| SCHEMBL560770 | 0.74 | PIK3CA (0.70) | ROCK2GSK3BPIM1AURKBKDR | |
| SCHEMBL561513 | 0.72 | GRM2 (0.43) | PRKAA1 | |
| SCHEMBL560718 | 0.71 | ACVR2A (0.43) | DYRK1A | |
| SCHEMBL29467448 | 0.67 | PDE2A (0.49) | MAPK1 | |
| SCHEMBL561004 | 0.67 | PDE2A (0.49) | MAPK1 | |
| SCHEMBL561036 | 0.67 | CHEK1 (0.46) | AURKBKDRJAK2CDK5CLK4 | |
| SCHEMBL16014174 | 0.66 | GSK3B (0.57) | TRPA1ROCK2GSK3BPIM1AURKB | |
| SCHEMBL16740690 | 0.66 | NOS1 (0.72) | TRPA1ROCK2GSK3BPIM1AURKB | |
| SCHEMBL29133371 | 0.66 | PDE2A (0.47) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653098-B2 | Pyrazolopyridine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653098-B2 | Pyrazolopyridine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653098-B2 | Pyrazolopyridine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| EP-2356117-B1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2356117-B1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20120035208-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2012-02-09 | — | — | US | disclosed |
| US-20120035208-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2012-02-09 | — | — | US | disclosed |
| US-20120035208-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2012-02-09 | — | — | US | disclosed |
| EP-2356117-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010059788-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035208-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PI4KA | TRPA1 1769/4885ROCK2 903/4885GSK3B 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.